Truist Financial Issues Positive Forecast for Integer (NYSE:ITGR) Stock Price

Integer (NYSE:ITGR) had its target price raised by equities research analysts at Truist Financial from $147.00 to $163.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price points to a potential upside of 16.71% from the company’s current price.

A number of other equities analysts also recently issued reports on the company. KeyCorp increased their price objective on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Citigroup increased their price target on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Wells Fargo & Company reissued an “overweight” rating and set a $160.00 price objective on shares of Integer in a research note on Tuesday, December 3rd. Benchmark raised their target price on shares of Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Bank of America boosted their price target on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $143.78.

Integer Trading Up 1.0 %

Shares of ITGR opened at $139.66 on Wednesday. Integer has a 1-year low of $89.65 and a 1-year high of $142.76. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. The firm’s 50-day moving average price is $132.80 and its 200-day moving average price is $125.29. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of 43.10, a PEG ratio of 2.00 and a beta of 1.12.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The business had revenue of $431.42 million for the quarter, compared to analysts’ expectations of $440.59 million. During the same period in the previous year, the firm posted $1.27 EPS. The business’s revenue was up 8.7% on a year-over-year basis. Sell-side analysts anticipate that Integer will post 5.33 EPS for the current year.

Institutional Trading of Integer

Institutional investors have recently added to or reduced their stakes in the business. Contravisory Investment Management Inc. grew its position in Integer by 55.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 80 shares during the period. Huntington National Bank increased its stake in shares of Integer by 8,933.3% in the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 268 shares in the last quarter. Quest Partners LLC increased its position in Integer by 3,688.9% in the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 332 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Integer by 74.1% in the third quarter. GAMMA Investing LLC now owns 653 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 278 shares during the period. Finally, Innealta Capital LLC bought a new stake in Integer during the 2nd quarter worth approximately $110,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.